سعر ايماتينيب مايلان 400مجم 30قرص 2026

Imatinib 400 mg film-coated tablets (pack of 30), a tyrosine kinase inhibitor anticancer medicine.

• Newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (adults and children)DailyMed (U.S. National Library of Medicine)
• Ph+ CML in blast crisis, accelerated phase, or chronic phase after interferon-alpha failureDailyMed (U.S. National Library of Medicine)
• Relapsed or refractory Ph+ acute lymphoblastic leukemia in adults; newly diagnosed Ph+ ALL in children with chemotherapyDailyMed (U.S. National Library of Medicine)

• Most frequently reported adverse reactions (>=30%): edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• The US Gleevec label lists no contraindications.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Edema and occasionally severe fluid retention (pleural or pericardial effusion, pulmonary edema, ascites) occur; weigh patients regularly and investigate unexpected rapid weight gain.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Anemia, neutropenia and thrombocytopenia occur and are managed with dose reduction, interruption or discontinuation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Severe congestive heart failure and left ventricular dysfunction have been reported, particularly in patients with comorbidities or cardiac risk factors.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducersMay reduce imatinib exposure; consider alternative agents.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inhibitors; grapefruit juiceMay significantly increase imatinib exposure; avoid grapefruit juice.DailyMed (U.S. National Library of Medicine)
• CYP3A4 and CYP2D6 substrates with a narrow therapeutic windowImatinib inhibits CYP3A4 and CYP2D6 and may increase their concentrations; use with caution.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on human and animal data; postmarketing reports include spontaneous abortions and congenital anomalies. Women should avoid pregnancy during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Imatinib and its active metabolite are excreted in human milk; do not breastfeed during treatment and for 1 month after the last dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Imatinib: Inhibits multiple tyrosine kinases including BCR-ABL, the PDGF receptor and the stem cell factor receptor (c-Kit).